The Quick Take
Quick summary: GrandeLASH-MD scores 7.8/10 under our editorial rubric. The dated label we reviewed lists isopropyl cloprostenate (IPCP). Our three-person panel first noticed visible changes around weeks 4-5, but that small, uncontrolled panel cannot prove what caused the changes or predict another person's results.
This three-person panel is the product-specific subgroup for this review within the broader 25+ tester-input program described on our homepage. It does not mean 25+ people tested this product.
Key Takeaways
- Label: the version checked lists IPCP; formula labels can change.
- Panel: three testers used the product for 12 weeks; this was not a randomized or controlled study.
- Regulatory context: Health Canada lists IPCP on its prohibited Cosmetic Ingredient Hotlist, and the SCCS published a negative safety conclusion for IPCP in 2026.
- Before using: ask an eye-care clinician about your own eyes, medicines, pregnancy, or breastfeeding questions.
All three testers reported visible changes during our 12-week use test. That is useful as an account of their experience, not proof of product efficacy. There was no look-alike control serum, blinding, random assignment, or clinical examiner.
The dated ingredient label we reviewed lists isopropyl cloprostenate. Formula labels can change, so check the package you receive. Health Canada’s current Cosmetic Ingredient Hotlist prohibits the prostaglandin family and specifically lists isopropyl cloprostenate. That regulatory fact does not tell us how often a reaction occurs in GrandeLASH-MD users or which ingredient caused our panel's results.
Review Snapshot
| Review factor | What our review found |
|---|---|
| Overall score | 7.8/10 |
| Formula status | Contains prostaglandin analogue |
| Primary appeal | our three-person panel first noted visible changes around weeks 4-5 |
| Main caveat | it contains isopropyl cloprostenate, a synthetic prostaglandin analogue |
| Price and size | $68 / 1mL-2mL |
| Expected timeline | not a promised timeline; panel observations began around weeks 4-5 |
| Evidence checked | Ingredient list, scoring rubric, user-review patterns, and category comparisons |
"I noticed visible changes while I used GrandeLASH-MD. At the time, I did not know its label listed isopropyl cloprostenate. I view that experience differently now. It was one person's observation, not proof that the product or IPCP caused the change."
✓ What We Liked
- Our three-person panel first reported visible changes around weeks 4-5
- Strong user satisfaction and ratings
- Multiple size options for different needs
- Multiple size options for different budgets
- Well-established brand with loyal following
✗ What Could Be Better
- Contains isopropyl cloprostenate (synthetic analogue)
- Active ingredient banned in Canadian cosmetics
- IPCP lacks a product-specific adverse-event rate in the sources reviewed
- Panel observations are not controlled clinical evidence
- Company doesn't prominently disclose active ingredient
Key Ingredients
Ingredient Snapshot
Names on the reviewed label and source notes that belong to the exact ingredient.
⚠️ Ingredient Alert
- Health Canada's current Hotlist prohibits the prostaglandin family and specifically lists isopropyl cloprostenate.
Read our complete Ingredient Guide to understand every ingredient
Our Full GrandeLASH MD Review
The Ingredient Safety Question
Let's be direct: the dated ingredient label we reviewed lists isopropyl cloprostenate, a prostaglandin analogue. Formula labels can change, so confirm the package in your hand. The brand also highlights vitamins and amino acids, but the ingredient list alone cannot tell us which ingredient caused a visible change.
Regulation differs by place. Health Canada’s current Cosmetic Ingredient Hotlist prohibits the prostaglandin family and specifically lists isopropyl cloprostenate. The SCCS concluded in 2026 that it could not consider IPCP, MDN, or DDDE safe for this cosmetic use, citing potent pharmacological activity and missing acceptable reproductive and developmental toxicity data.
The LATISSE prescribing label is evidence about bimatoprost, not IPCP. It warns that iris pigmentation may be permanent, reports lid pigmentation, and lists periorbital and lid changes associated with fat atrophy among postmarketing reports whose frequency cannot be estimated. LATISSE findings cannot be transferred to IPCP or GrandeLASH-MD. This evidence does not prove that IPCP alone caused GrandeLASH-MD’s results and does not establish a GrandeLASH-MD adverse-event rate.
GrandeLASH-MD Ingredient Deconstruction
Understanding the ingredient list matters, but a label is not a clinical study. Here is what we can say without guessing which ingredient drove an outcome:
Ingredient of regulatory interest: isopropyl cloprostenate. IPCP is a prostaglandin analogue. SCCS describes potent pharmacological activity for the assessed analogues, even at low concentrations, but the sources reviewed do not prove the size of IPCP's effect in this finished product.
Peptides and amino acids. The reviewed label includes amino acids and myristoyl pentapeptide-17. We found no controlled human study showing that myristoyl pentapeptide-17 alone grows lashes, and this product was not tested ingredient by ingredient.
Conditioning agents: hyaluronic acid, panthenol, vitamin E. These are used in cosmetics for conditioning or water-binding roles. Their presence does not prove a growth effect or rule out irritation from the finished formula.
Botanical extracts: chamomile and green tea. These appear on the reviewed label. We did not find product-level evidence that isolates their contribution.
The bottom line: the label tells us GrandeLASH-MD contains IPCP, peptides, amino acids, and conditioners. It does not prove which ingredient caused a result. A prostaglandin-free label removes the covered analogue names from that label check, but does not prove another formula is effective, irritation-free, or safe during pregnancy.
Our Testing Experience
Our small, uncontrolled three-person panel used GrandeLASH-MD for 12 weeks. The applicator was a thin wand, and testers found the clear formula quick to dry. These are use observations, not clinical evidence.
All three testers first reported visible changes around weeks 4-5. They described longer- and darker-looking lashes by the end of the test. With only three testers and no control serum, we cannot estimate an average effect, compare products reliably, or identify which ingredient caused the change.
One tester reported mild lash-line redness around week 6 and paused use. That is one panel observation. It does not establish causation, frequency, or how another person will respond.
How to Use GrandeLASH-MD
Follow the current package directions and keep the applicator clean. The steps below describe how our panel applied the product; they are not medical instructions or a promise of results:
Step 1: Start with clean, dry skin. The current official directions say not to apply over makeup, other skin-care products, or wet skin. They do not say that an oil-free cleanser is required or that oil residue prevents absorption.
Step 2: Use one dip for both upper lash lines. The current official directions say to use one dip and one single stroke along each upper lash line, like liquid eyeliner. Do not apply to the lashes, lower lash line, or inner tear duct.
Step 3: Blot any excess. If you see pooling or dripping, blot it with a clean tissue and follow the brand's directions. Avoid getting cosmetic serum in the eye.
Step 4: Let it dry. Grande's current official pages conflict: its trial-use page says 1 to 2 minutes, while its application tips page says 2 to 3 minutes. Follow the package you receive or ask Grande to clarify. The brand says to apply once daily; it does not require night-only use.
Step 5: Follow the current label. Do not apply more often than directed. A panel timeline is not a personal dosing schedule or promised result date.
Our panel found application quick. Tingling or redness is not proof that a product is working. Stop use and ask a clinician if you develop persistent eye or eyelid symptoms.
Lash Dependency and Discontinuation
We did not run a controlled discontinuation study for GrandeLASH-MD. The LATISSE label says bimatoprost-related lash growth is expected to return to the pretreatment level after stopping, but that statement is specific to bimatoprost and cannot be transferred to IPCP or GrandeLASH-MD.
Some user reviews describe losing visible changes after stopping, but anecdotes cannot establish a product-wide timeline. Treat continued purchase as a possible cost, not a proven dependency schedule.
Who GrandeLASH-MD Is For
This review may help people who want to compare a current label, our limited panel observations, and regulatory sources. It cannot decide whether the product is appropriate for your eyes or health history.
If you have an eye condition, use eye medicine, are pregnant or breastfeeding, or have had eyelid reactions, ask your eye-care clinician or prescriber before use. You can compare labels with LATISSE and RevitaLash, but do not assume different analogues have identical effects or event rates.
GrandeLASH-MD Before and After: Week-by-Week Panel Observations
Here is what our three testers documented over 12 weeks. We did not use a control serum, blinding, or random assignment. The LATISSE label says bimatoprost's precise mechanism is unknown; we did not find controlled product evidence proving that IPCP acts identically in GrandeLASH-MD.
GrandeLASH-MD Across 12 Weeks
Three individual timelines, not a product-wide efficacy or safety rate.
Weeks 1-2: No tester reported a visible lash change. Two reported brief tingling, and one reported slight lash-line redness on day 3. These sensations do not show that an ingredient reached a follicle or that the product was working.
Weeks 3-4: All three testers described early visible changes by the end of week 4. One tester measured about 1 mm of additional length. With three people and no control, these observations do not establish an expected result or a reliable comparison with another formula.
Weeks 5-8: Testers described lashes as longer-, thicker-, and darker-looking. One tester reported persistent mild lash-line redness around week 6 and paused use for three days. We cannot determine from this panel whether the product caused either the visible change or the redness.
Weeks 9-12: Our panel measurements ranged from 1.8 to 2.2 mm of additional lash length by week 12. One tester also reported subtle upper-lid darkening around week 10 that remained at the end of the test. We did not diagnose the change, prove its cause, or follow it after week 12.
The timeline documents what happened to three people. It does not establish average efficacy, a safety rate, or what will happen after a user stops.
The Beauty Routine Experience
GrandeLASH-MD uses a thin, firm-bristled wand that is one of the better designs in the category. The wand is narrow enough to draw a precise line along the upper lash line without excess spreading, and the bristles are stiff enough to maintain control. It is a meaningfully better design than what you get from The Ordinary or many other budget options.
The formula is clear, thin, and slightly viscous. Our panel found it easy to spread in a thin line. The current brand pages say one dip should cover both upper lash lines, but they conflict between a 1-to-2-minute and 2-to-3-minute dry time. Follow the directions on the package you receive.
Two of our three testers reported brief tingling during the first week. The brand advises applying to a clean, dry upper lash line and waiting before adding other eye products. Our panel noticed more product movement when layering too soon, but this observation does not prove a link to any later skin change.
GrandeLASH-MD vs Gentler Alternatives
The biggest decision when choosing a lash enhancing serum is whether you're comfortable with synthetic analogues. GrandeLASH MD contains one. Many popular alternatives do not. Here's how they compare:
Observed timing: our GrandeLASH-MD panel first reported visible changes around weeks 4-5. No controlled head-to-head study reviewed here shows that IPCP formulas work faster than peptide formulas or that their results are comparable.
Label difference: the peptide formulas linked in our prostaglandin-free guide did not list the covered analogue names when checked. That does not prove they are irritation-free, safe during pregnancy, or effective.
After stopping: we did not test discontinuation for GrandeLASH-MD or a peptide comparator. Use each product only as its current label directs.
Comparison to other labels: LATISSE is a prescription bimatoprost product with an FDA-reviewed label. The dated labels we reviewed for RevitaLash, NeuLash, and RapidLash listed other prostaglandin analogues. Different ingredients and finished formulas should not be treated as interchangeable.
For a complete ranking of every serum we've tested, sorted by our safety-weighted scoring methodology, see our full rankings.
Value Analysis
GrandeLASH-MD is sold in two sizes: 1mL for $36 (lasting roughly 6-8 weeks) and 2mL for $68 (lasting roughly 3 months). The 2mL size works out to approximately $22.67 per month or $0.76 per day, while the smaller size runs closer to $18-24 per month depending on how conservatively you use it. This is mid-range pricing, significantly cheaper than RevitaLash ($25-33/month) and competitive with premium peptide formulas like Vegamour.
If a user follows the current once-daily directions for a full year, the listed sizes imply an ongoing cost rather than a one-time purchase. At the price captured for this review, our estimate was about $272 per year. Actual use, prices, and replacement timing vary, so check current directions and pricing.
Annual Cost: GrandeLASH-MD vs Alternatives
What a year of lash growth actually costs across three approaches.
Archived Reader Anecdotes About GrandeLASH-MD
Source limit: We do not publish source URLs or a verification method for these archived quotes. We exclude them from evidence conclusions, structured data, and AI-readable mirrors. Treat each as an unverified personal report.
I know people have concerns about the ingredients but this stuff WORKS. My lashes have never been this long. Been using it for 6 months and I love the results. My before and after photos don't even look like the same person.
Works well but made my eyelids slightly darker after a few months. Switching to a gentler option. Something to be aware of if you use it daily.
On my fourth tube. I tried switching to a "clean" serum and lost all my progress within 2 months. Came right back. I love Grande Lash so much I can't quit it. Nothing else compares to the actual growth you see in photos.
Fast results but I wish I'd known about the ingredient concerns before starting. My eyes get red if I use it every single night, so I do every other day now and it still works decently.
I love this GrandeLash serum. People keep asking if my lashes are extensions. I don't even need mascara anymore, and the before and after difference is wild. My only complaint is the price adds up since you can't stop using it.
I stopped using it after 3 months because of the lawsuit news. My lashes were gorgeous but I don't love the idea of putting synthetic compounds near my eyes every night. Currently trying a gentler alternative instead.
The user reviews we sampled often praised visible changes and ease of use. These are self-reported anecdotes, not a representative efficacy estimate or controlled evidence.
Other sampled reviews mentioned eyelid darkening, irritation, or losing visible changes after stopping. This convenience sample cannot rank complaints, establish causation, or estimate how often an event occurs.
GrandeLASH MD: Frequently Asked Questions
Does GrandeLASH serum actually work?
Our three testers reported visible changes and measured 1.8-2.2 mm of additional length by week 12. This small, uncontrolled panel cannot prove that IPCP caused the change, estimate an average result, or predict a stopping timeline. We found no controlled product study in the sources reviewed.
Why is GrandeLASH getting sued?
Lawsuits have alleged inadequate disclosure of IPCP. Allegations are not proof of medical causation. Our evidence assessment instead relies on the dated product label, Health Canada's Hotlist, and the SCCS opinion linked above.
What does Kim Kardashian use for eyelash growth?
We do not use a celebrity's routine as product evidence. LATISSE is a prescription bimatoprost product; GrandeLASH-MD lists IPCP. Evidence about one should not be transferred to the other.
Is GrandeLASH MD safe to use?
No single source reviewed proves this finished product safe for everyone. Health Canada's current Hotlist prohibits the prostaglandin family and specifically lists IPCP. The SCCS concluded in 2026 that it could not consider IPCP, MDN, or DDDE safe for this cosmetic use. Those conclusions do not establish a GrandeLASH-MD adverse-event rate. Ask an eye-care clinician about your circumstances.
How long does GrandeLASH take to work?
Our three testers first reported visible changes around weeks 4-5. That is a panel observation, not a promised result window or proof that IPCP caused the change. Follow the current label and judge your own response without assuming another user's timeline.
Our Verdict on GrandeLASH-MD
Our 7.8/10 score combines label transparency, price, use experience, sampled reviews, and our three-person panel. It is not a medical safety grade. The panel reported visible changes, while current Canadian and SCCS sources raise material concerns about IPCP. This review cannot prove a product-specific event rate, identify IPCP as the sole cause of the panel's results, or show that another formula is risk-free.